Karyopharm Therapeutics Inc. KPTI
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology drug developer. Its lead program, XPOVIO (selinexor), is in Phase 3 for Multiple myeloma (approved); myelofibrosis in development. Its next catalyst on record is selinexor + pomalidomide + dexamethasone (EMN29): Topline data from event-driven Phase 3 (European Myeloma Network sponsored) (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: selinexor + pomalidomide + dexamethasone (EMN29) — Topline data from event-driven Phase 3 (European Myeloma Network sponsored) (H2 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| XPOVIO (selinexor) - multiple myeloma | Multiple myeloma (BOSTON and STORM-based indications; FDA approved 2019) | small molecule | Approved |
| selinexor + ruxolitinib (SENTRY) | JAK inhibitor-naive myelofibrosis (Phase 3 complete; sNDA for accelerated approval planned Aug 2026) | small molecule | Phase 3 |
| selinexor (XPORT-EC-042) | TP53 wild-type advanced/recurrent endometrial cancer maintenance (Phase 3 did not meet primary endpoint, Jul 2026) | small molecule | Phase 3 |
| selinexor monotherapy (SENTRY-2) | JAKi-naive myelofibrosis with moderate thrombocytopenia | small molecule | Phase 2 |
| eltanexor | Additional myeloproliferative neoplasms / TP53 wild-type tumors (exploratory, funding-dependent) | small molecule | Pre-clinical |
Recent results and decisions
- Aug 31, 2026submitted sNDA submitted to FDA seeking Accelerated Approval of selinexor plus ruxolitinib in myelofibrosis; Priority Review requested.
it has submitted a supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) seeking Accelerated Approval for XPOVIO® (selinexor) in combination with ruxolitinib for patients with myelofibrosis
Filing - Jul 30, 2026missed XPORT-EC-042 missed its PFS primary endpoint; mITT median PFS 12.75 vs 7.43 months, HR 0.76 (95% CI 0.51-1.12), one-sided p=0.0791.
The trial did not meet its primary endpoint of progression free survival (“PFS”).
Filing - May 14, 2026completed enrollment Phase 3 XPORT-EC-042 completed enrollment: 257 patients ITT, about 220 in the mITT population.
Completed enrollment of the Phase 3 XPORT-EC-042 trial (NCT05611931), which is evaluating selinexor as a maintenance-only therapy following systemic therapy versus placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.